Literature DB >> 19224107

Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects.

Patrik Roser1, Jürgen Gallinat, Gordon Weinberg, Georg Juckel, Inge Gorynia, Andreas M Stadelmann.   

Abstract

Abnormalities in psychomotor performance are a consistent finding in schizophrenic patients as well as in chronic cannabis users. The high levels of central cannabinoid (CB(1)) receptors in the basal ganglia, the cerebral cortex and the cerebellum indicate their implication in the regulation of motor activity. Based on the close relationship between cannabis use, the endogenous cannabinoid system and motor disturbances found in schizophrenia, we expected that administration of cannabinoids may change pattern of psychomotor activity like in schizophrenic patients. This prospective, double-blind, placebo-controlled cross-over study investigated the acute effects of cannabinoids on psychomotor performance in 24 healthy right-handed volunteers (age 27.9 +/- 2.9 years, 12 male) by comparing Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and standardized cannabis extract containing Delta(9)-THC and cannabidiol. Psychomotor performance was assessed by using a finger tapping test series. Cannabis extract, but not Delta(9)-THC, revealed a significant reduction of right-hand tapping frequencies that was also found in schizophrenia. As to the pure Delta(9)-THC condition, left-hand tapping frequencies were correlated with the plasma concentrations of the Delta(9)-THC metabolite 11-OH-THC. These effects are thought to be related to cannabinoid actions on CB(1) receptors in the basal ganglia, the cerebral cortex and the cerebellum. Our data further demonstrate that acute CB(1) receptor activation under the cannabis extract condition may also affect intermanual coordination (IMC) as an index of interhemispheric transfer. AIR-Scale scores as a measure of subjective perception of intoxication were dose-dependently related to IMC which was shown by an inverted U-curve. This result may be due to functional changes involving GABAergic and glutamatergic neurotransmission within the corpus callosum.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224107     DOI: 10.1007/s00406-009-0868-5

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  58 in total

1.  Functional motor asymmetries correlated with clinical findings in unmedicated schizophrenic patients.

Authors:  I Gorynia; R Uebelhack
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

Review 2.  The role of the corpus callosum in interhemispheric transfer of information: excitation or inhibition?

Authors:  Juliana S Bloom; George W Hynd
Journal:  Neuropsychol Rev       Date:  2005-06       Impact factor: 7.444

3.  Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use.

Authors:  B Dean; S Sundram; R Bradbury; E Scarr; D Copolov
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

4.  Intermanual coordination in relation to different clinical subgroups in right-handed patients with schizophrenic and other psychotic disorders.

Authors:  Inge Gorynia; Vincent Campman; Ralf Uebelhack
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2003-02       Impact factor: 5.270

5.  Regional cortical dysfunction in schizophrenic patients studied by computerized neuropsychological methods.

Authors:  S E Levander; A Bartfai; D Schalling
Journal:  Percept Mot Skills       Date:  1985-10

6.  Psychomotor disturbances in psychiatric patients as a possible basis for new attempts at differential diagnosis and therapy. II. Cross validation study on schizophrenic patients: persistence of a "psychotic motor syndrome" as possible evidence of an independent biological marker syndrome for schizophrenia.

Authors:  W Günther; R Günther; F X Eich; E Eben
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1986

7.  Cannabis consumption as a prognostic factor in schizophrenia.

Authors:  M J Martinez-Arevalo; A Calcedo-Ordoñez; J R Varo-Prieto
Journal:  Br J Psychiatry       Date:  1994-05       Impact factor: 9.319

Review 8.  Cannabis and the brain.

Authors:  Leslie Iversen
Journal:  Brain       Date:  2003-06       Impact factor: 13.501

9.  Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.

Authors:  Patrik Roser; Georg Juckel; Johannes Rentzsch; Thomas Nadulski; Jürgen Gallinat; Andreas M Stadelmann
Journal:  Eur Neuropsychopharmacol       Date:  2008-06-10       Impact factor: 4.600

10.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

View more
  17 in total

Review 1.  Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.

Authors:  John M McPartland; Marnie Duncan; Vincenzo Di Marzo; Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2015-02       Impact factor: 8.739

2.  Altered brain activation during visuomotor integration in chronic active cannabis users: relationship to cortisol levels.

Authors:  George R King; Thomas Ernst; Weiran Deng; Andrew Stenger; Rachael M K Gonzales; Helenna Nakama; Linda Chang
Journal:  J Neurosci       Date:  2011-12-07       Impact factor: 6.167

3.  Cortico-cerebellar abnormalities in adolescents with heavy marijuana use.

Authors:  Melissa P Lopez-Larson; Jadwiga Rogowska; Piotr Bogorodzki; Charles Elliott Bueler; Erin C McGlade; Deborah A Yurgelun-Todd
Journal:  Psychiatry Res       Date:  2012-07-24       Impact factor: 3.222

Review 4.  Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence.

Authors:  Madison Wright; Patricia Di Ciano; Bruna Brands
Journal:  Cannabis Cannabinoid Res       Date:  2020-09-02

Review 5.  Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences.

Authors:  Natania A Crane; Randi Melissa Schuster; Paolo Fusar-Poli; Raul Gonzalez
Journal:  Neuropsychol Rev       Date:  2012-11-06       Impact factor: 7.444

6.  A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains.

Authors:  L Cinnamon Bidwell; Raeghan Mueller; Sophie L YorkWilliams; Sarah Hagerty; Angela D Bryan; Kent E Hutchison
Journal:  Cannabis Cannabinoid Res       Date:  2018-03-01

7.  Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.

Authors:  Margaret Haney; Robert J Malcolm; Shanna Babalonis; Paul A Nuzzo; Ziva D Cooper; Gillinder Bedi; Kevin M Gray; Aimee McRae-Clark; Michelle R Lofwall; Steven Sparenborg; Sharon L Walsh
Journal:  Neuropsychopharmacology       Date:  2015-12-28       Impact factor: 7.853

8.  Developing a phone-based measure of impairment after acute oral ∆9-tetrahydrocannabinol.

Authors:  Elisa Pabon; Harriet de Wit
Journal:  J Psychopharmacol       Date:  2019-08-13       Impact factor: 4.562

9.  Cannabis Use: Neurobiological, Behavioral, and Sex/Gender Considerations.

Authors:  Anahita Bassir Nia; Claire Mann; Harsimar Kaur; Mohini Ranganathan
Journal:  Curr Behav Neurosci Rep       Date:  2018-11-10

Review 10.  Cannabis and Cognitive Functioning: From Acute to Residual Effects, From Randomized Controlled Trials to Prospective Designs.

Authors:  Josiane Bourque; Stéphane Potvin
Journal:  Front Psychiatry       Date:  2021-06-10       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.